fsma helps standardize that. the firm has to plan when there's a hazard to make sure there's some kind of plan to address recalls in particular, whereas before it was more reactive. >> common sense, if you don't have a plan, then it truly would be haphazard at best. so i would hope your inspectors were in there every day, constantly making sure the ts are being crossed, the is dotted. >> thank you, congressman. i got a note related to your earlier question. we are at about 1200 products class one out of our 36 -- little more than 3600. that's roughly a third. >> that's actually higher than i might have expected. i only have a few seconds left. how often does your lab do independent testing versus relying on the company data to assess the risk? >> we do part of the things you mentioned and some of these where we have a -- there's a certain risk profile if it hits a certain risk profile, we do testing in the environment of that facility. in addition, if we have reason to, we have different types of surveillance tes

>> we are actively working on fsma implementation now. i'm very much engaged in that myself. and i don't have anything today. i can bring that back to the agency if there's anything else to add. >> thank you. i yield back. >> gentle lady yields back. the chair will now recognize the gentleman from georgia, mr. carter, for five minutes. >> thank both of you for being here. this is a very important subject particularly for us in the state of georgia. we had the unfortunate incident some years ago with the peanuts. that's still fresh in our minds. mr. stearn, when you released the updated guidance yesterday on accelerating the recall process, part of it included stepping in if a company for the fda didn't -- for the fda to step in if a company hadn't sufficiently addressed the recall. how do you ferm if they've sufficiently addressed it or not. >> the guidance yesterday, we released talking about public warning and notification. it talks about when we think a company should issue a warning and we describe how that should be done and when fda will issue public warnings as well as